We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.
Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Stabilization Platform Assists Endolumenal Interventions

By HospiMedica International staff writers
Posted on 15 May 2018
Print article
Image: An endoscopic accessory stabilizes endoluminal procedures (Photo courtesy of Lumendi).
Image: An endoscopic accessory stabilizes endoluminal procedures (Photo courtesy of Lumendi).
A novel accessory ensures complete positioning of an endoscope in the large intestine and assists with optical visualization, diagnosis, and treatment.

The Lumendi (High Wycombe, United Kingdom) DiLumen C2 is an endolumenal interventional platform that consists of a soft flexible sheath that fits over standard and small diameter endoscopes. The device employs two balloons, one behind the bending section of the endoscope and the second in front of the tip. When both balloons are deployed and inflated, the area in between the two balloons is stabilized, creating a therapeutic zone that facilitates stabilization, insufflation, and manipulation of the tissue, thus allowing the clinician to more effectively treat the target area.

The platform also includes two six mm diameter tool channels, which accommodate two independent flexible articulating hand instruments, such as a flexible grasper called the DiLumen Ig, which can be used together with the DiLumen C2 to grasp and manipulate mucosal tissue. Several additional flexible articulating instruments are under development, and will be available for cutting and dissection of tissue. Once the therapy is completed the balloons are simply deflated and removed, along with the colonoscope.

“We are continuing our commitment to develop innovative devices that facilitate endolumenal procedures for many gastrointestinal interventions in an effort to reduce costs and improve patient outcomes,” said Dr. Peter Johann, CEO of Lumendi. “To date, we have completed over 350 procedures with the commercially available DiLumen EIP, with no serious adverse events.”

Related Links:

Print article


Copyright © 2000-2019 Globetech Media. All rights reserved.